Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)
Background: Arbaclofen, the active R-enantiomer of baclofen, a racemic g-aminobutyric acid-B (GABAB) receptor agonist, has been a mainstay...
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)
Background: Despite pharmacologic therapy, people with multiple sclerosis (MS) often experience spasticity, which can worsen with longer...
Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004
Background: Arbaclofen is the active R-enantiomer of racemic baclofen. Arbaclofen extended-release (ER) tablets have demonstrated efficacy...
Treating Minority Patients with Multiple Sclerosis: Development of the CHIMES Trial
Background: Black, African American (AA) and Hispanic/Latino (HA) patients with multiple sclerosis (MS) have greater disease severity and...
COVID-19 in Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease Patients in North America
Background: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raised...